Chapter,
Chapter 40 Common confounders when evaluating noninvasive protein biomarkers
,
Editors:
DOI:
Contributors
Willumsen, Nicholas
0000-0002-5207-5173
[1]
Nissen, Neel Ingemann
0000-0002-8970-8798
[1]
Karsdal, Morten Asser
0000-0002-4764-5100
[1]
Affiliations
- [1] Nordic Bioscience (Denmark) [NORA names: Nordic Bioscience; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
Noninvasive protein biomarkers are becoming an increasingly important factor in medical practice and clinical trial design. Such quantifiable molecular biomarkers can serve as early surrogate endpoints of an eventual clinical outcome and/or identify patients most likely to respond to a specific therapy. Noninvasive biomarkers offer several advantages over tissue-based markers; however, it is important to be familiar with potential common confounders that may impact the interpretation of the results and hence the clinical decision-making.
Keywords
biomarkers,
clinical decision-making,
clinical outcomes,
clinical trial design,
confounding,
decision-making,
design,
endpoint,
eventual clinical outcome,
factors,
interpretation,
markers,
medical practice,
molecular biomarkers,
noninvasive biomarkers,
outcomes,
patients,
practice,
protein biomarkers,
results,
surrogate endpoints,
therapy,
tissue-based markers,
trial design
